$VBIO News

Valion Bio Advances U.S. Department Of War And BARDA Engagement On Entolimod Radiation Countermeasure; Highlights Interest In Oral Formulation For Field Deployment And National Stockpiles

Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript

Valion Bio Q1 2026 Earnings Call: Complete Transcript

Valion Bio's Velocity Bioworks Enters Into Exclusive Commercial Development And License Agreement With LarmorBio For BioScan-NMR Platform

Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY

Valion Bio Receives First Study Protocol Under Non-Clinical Evaluation Agreement With National Institute Of Allergy And Infectious Diseases; NIAID To Fully Fund In Vivo Studies Required To Support BLA For Entolimod Under FDA's Animal Rule Pathway

Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening

Tivic Health Systems Rebranding To Valion Bio Effective April 28, Ticker To Begin Trading Under Ticker "VBIO"

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Tivic Health Systems Receives Ukraine Health Ministry RFI To Evaluate Entolimod For Radiation Countermeasure Use; Pre-Submission Meeting Requested

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Tivic Health Systems Inks Agreement With National Institute Of Allergy And Infectious Diseases To Fund, Conduct Preclinical Trials Of Entolimod For Gastrointestinal Acute Radiation Syndrome

Tivic Reports Full Year 2025 Results

Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript

Tivic Health Systems Continues To Advance Entolimod Platform Toward Potential Funding Partnerships

'Tivic Health Aims To Advance Immunotherapy Research Programs' - USA Today

Tivic Health CEO Letter to Shareholders

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma